Local Company to Offer Testing for Breast Cancer Gene

Pathway Genomics is preparing to offer the tests

View Comments ()



    Advocates for breast cancer patients are ecstatic about the Supreme Court ruling that ended a patent on genetic screening tests for a breast cancer gene.

    Now San Diego company Pathway Genomics is preparing to offer a more affordable test to patients.

    Local Company to Offer Cancer Screening Test

    [DGO] Local Company to Offer Cancer Screening Test
    One local company is already preparing to offer a more affordable test to patients after the Supreme Court ended a patent on genetic testing for breast cancer. (Published Saturday, June 15, 2013)

    Angelina Jolie tested positive for a genetic mutation that makes breast and ovarian cancer extremely likely. And after the Supreme Court ruled that DNA tests for those mutations cannot be patented, testing will get cheaper.

    That's good news for cancer victim advocates who worry about women who are uninsured.

    Jolie's Uncle Advises Cancer Screenings

    [DGO]Jolie's Uncle Advises Cancer Screenings
    Less than two weeks after Angelina Jolie's double mastectomy, her aunt dies of breast cancer. Debbie Martin's husband Ron talks exclusively to NBC 7 San Diego about her battle with the deadly disease. (Published Tuesday, May 28, 2013)

    “These tests, these lifesaving tests will be much more affordable for all of us regardless of how much money is in your pocket.” said Laura Farmer Sherman from the Susan G. Komen chapter in San Diego.

    The company Myriad Genetics held the patent for testing on what's called the BRCA1 and BRCA2 genes, and charged anywhere between $3,000-7,000.

    Dr. Snyderman Discusses Ovary Removal

    [DGO] Dr. Snyderman Discusses Ovary Removal
    NBC Chief Medical Editor Dr. Nancy Snyderman talks to Christine Haas about why Angelina Jolie is reportedly removing her ovaries. (Published Wednesday, May 15, 2013)

    After the Supreme Court ruling, local company Pathway Genomics announced that it will offer tests on those genes, and others will likely follow.

    “It will result in other laboratories that have the capability of Pathway to offer these tests at a substantially lower price point,” said Jim Plante, the Pathway Genomics Founder and CEO.

    Pathway Genomics would not say how much it will charge but promises it will be much less than $3,000.

    With an estimated 40,000 people expected to die of breast cancer this year, Pathway Genomics hopes the effects of cheaper genetic testing will be profound.

    “It could potentially save tens of thousands, if not hundreds of thousands of lives, said Plante.

    Follow NBC 7 for the latest news, weather, and events: iPad App | iPhone App | Android App | Facebook | Twitter | Google+ | Instagram | RSS | Text Alerts | Email Alerts